Amgen Inc. (NASDAQ:AMGN) Shares Sold by International Assets Investment Management LLC

International Assets Investment Management LLC lowered its position in Amgen Inc. (NASDAQ:AMGN) by 98.6% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 36,265 shares of the medical research company’s stock after selling 2,487,122 shares during the period. International Assets Investment Management LLC’s holdings in Amgen were worth $9,452,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Capital Performance Advisors LLP purchased a new stake in Amgen during the 3rd quarter valued at about $25,000. Hershey Financial Advisers LLC purchased a new stake in shares of Amgen in the second quarter valued at approximately $30,000. Legacy Investment Solutions LLC acquired a new stake in shares of Amgen in the third quarter valued at approximately $29,000. Matrix Trust Co purchased a new position in Amgen during the third quarter worth approximately $36,000. Finally, Livelsberger Financial Advisory acquired a new position in Amgen during the third quarter worth $56,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Down 0.3 %

Amgen stock traded down $0.70 during trading on Wednesday, reaching $261.36. 347,619 shares of the company’s stock were exchanged, compared to its average volume of 2,679,296. The firm has a market cap of $140.49 billion, a price-to-earnings ratio of 33.46, a PEG ratio of 2.91 and a beta of 0.56. The company’s 50-day moving average is $282.38 and its two-hundred day moving average is $309.78. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The firm had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm’s revenue was up 23.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $4.96 earnings per share. On average, analysts predict that Amgen Inc. will post 19.53 earnings per share for the current year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be paid a $2.38 dividend. This is an increase from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a yield of 3.64%. The ex-dividend date is Friday, February 14th. Amgen’s payout ratio is presently 121.90%.

Wall Street Analyst Weigh In

AMGN has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft reduced their price target on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Sanford C. Bernstein initiated coverage on shares of Amgen in a research note on Thursday, October 17th. They issued an “outperform” rating and a $380.00 price target for the company. Piper Sandler reduced their price target on shares of Amgen from $344.00 to $310.00 and set an “overweight” rating on the stock in a research report on Thursday, January 2nd. Bank of America reiterated an “underperform” rating and issued a $256.00 price objective on shares of Amgen in a research report on Tuesday, December 10th. Finally, Wolfe Research initiated coverage on Amgen in a research report on Friday, November 15th. They issued a “peer perform” rating on the stock. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $317.30.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.